Related Experiment Videos
Felbamate relieved trigeminal neuralgia
1Department of Neurology, Mayo Clinic Jacksonville, FL 32224, USA.
The Clinical Journal of Pain
|June 1, 1995
Summary
Felbamate effectively reduced severe trigeminal neuralgia pain in a small trial. However, serious safety concerns led to its discontinuation for non-cancer pain management.
Area of Science:
- Neurology
- Pharmacology
Background:
- Trigeminal neuralgia is a debilitating neuropathic pain condition.
- Limited treatment options exist for severe, refractory cases.
Observation:
- A novel anticonvulsant, felbamate, was investigated for its analgesic properties in three patients with severe trigeminal neuralgia.
- Patients had failed other treatments and opted against surgery.
Findings:
- Felbamate demonstrated potent pain relief in trigeminal neuralgia patients.
- The drug was generally well-tolerated during the study period.
- Subsequent reports linked felbamate to aplastic anemia and hepatic failure in epilepsy patients, prompting withdrawal.
Implications:
- Felbamate shows promise for trigeminal neuralgia but carries significant risks.
- Potential mechanisms involve stabilizing neuronal membrane depolarization.
- Further development of felbamate for non-malignant pain is not recommended due to safety concerns.
- Anticonvulsant drug screening principles may inform the search for novel analgesics.